SynthesisStem cells translational medicine2026
Isolation and characterization of human multilineage-differentiating stress-enduring cells for use in tissue engineering: a systematic review.
Synthesis in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Human multilineage-differentiating stress-enduring (MUSE) cells represent a promising cell population for tissue engineering and translational medicine owing to their intrinsic pluripotency and stress resistance. MUSE cells express pluripotency markers such as SSEA-3, Nanog, Sox2, and Oct3/4, while maintaining their immunomodulatory capabilities. This systematic review (PROSPERO CRD42024532621) analyzed studies on human MUSE cell isolation, characterization, and translational potential through searches of the PubMed, Scopus, and Web of Science databases in April 2024. The TIDieR and SYRCLE checklists were used to assess the risk of bias. Our findings identified 34 studies that followed the PRISMA guidelines for assessing different tissue sources, isolation techniques, and characterization methods. MUSE cells are primarily obtained from bone marrow mesenchymal stem cells, and fluorescence-activated cell sorting is the predominant isolation method. Characterization was mainly performed using SSEA-3 immunodetection (positivity ranged from <1% to 6.30%) and was linked to the expression of pluripotency and mesenchymal markers. These findings highlight the relevance of MUSE cells in regenerative medicine as a distinct pluripotent subpopulation within adult mesenchymal tissues. In addition, SSEA-3-based isolation approaches complemented by functional assays has emerged as a key methodological approach for the reliable identification and characterization of MUSE cells. However, isolation efficiency varies depending on the cell source and method. Standardized protocols are, therefore, needed to improve reproducibility and facilitate the translational development of MUSE cell-based regenerative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.